Background: The combination of gemcitabine and cisplatin has proven effective in the treatment of advanced non-small-cell lung cancer (NSCLC). However, the optimal schedule for administration of the two drugs has not yet been determined. In this study we evaluated the activity and toxicity of a weekly gemcitabine and cisplatin schedule.
Introduction
Lung cancer is the-principal cause of cancer deaths in Western countries [1] .
NSCLC accounts for 75% to 80% of primary lung neoplasms [2] . Metastatic or unresectable locally advanced NSCLC has a very poor prognosis and treatment is only marginally effective. Meta-analyses have demonstrated a significant survival benefit of 10% at one year for patients treated with cisplatin-based chemotherapy compared with best supportive care [3, 4] .
Gemcitabine (2',2'-difluorodeoxicytidine) is a nucleoside analog structurally similar to ara-C but with different pharmacokinetics, greater activity in solid tumors and a favourable toxicity profile [5] . Phase II studies of weekly gemcitabine in advanced NSCLC have shown response rates between 20% and 26% [6] . Furthermore, both in vitro and in vivo studies suggested a synergistic interaction between gemcitabine and cisplatin [7] . On the basis of these observations, a moderate number of phase II trials with gemcitabine and cisplatin were conducted in the treatment of advanced NSCLC in chemotherapy-naive patients [8] [9] [10] [11] [12] [13] (Table 1) .
The primary endpoint of this multicentric phase II study was to evaluate the activity and toxicity of a schedule employing gemcitabine and cisplatin, both given three out of four weeks. Secondary endpoints were: 1) evaluation of median survival time; 2) evaluation of performance status before and after two cycles of chemotherapy.
Patients and methods

Patient selection
Eligibility criteria included histologically or cytologically proven stage IIIB-IV NSCLC with bidimensionally measurable lesions, no previous treatment, ECOG performance status sS2, age ^7 5 years, leukocyte count >3.0 x 10 9 /l (absolute granulocyte count ^1.5 x 10 9 /l), platelet count Js 100 x 10 9 /l, haemoglobin level > 10 g/1, serum creatinine level <0.15 mmol/1, hepatic enzyme levels no more than three times those of control (five times those of control in instances of liver metastases) and no bone or brain metastases as the only measurable site of disease. The study protocol was approved by local ethics committees and all patients gave informed consent.
Staging procedures included physical examination, chest X-ray, chest-abdomen CTscan, bone scan and optional bronchoscopy. Brain CTwas performed if clinically indicated. Anton et al. [11] Crino et al. [8] Einhorn [13] 36 
Treatment plan
Gemcitabine, 1000 mg/m 2 i.v., and cisplatin, 35 mg/m 2 i.v., were given on days 1, 8, and 15 followed by one week of rest. Before gemcitabine, patients received intravenous corticosteroids to preclude a flu-like syndrome; cisplatin was administered immediately after gemcitabine, with adequate intravenous hydration (750 ml normal saline over 60 minutes before and 1000 ml over 90 minutes after cisplatin) and parenteral administration of 5-HT 3 receptor antagonists. In succeeding weeks, administration of both drugs was reduced or omitted in instances of toxicity according to the protocol dosage adjustment criteria: in instances of absolute granulocyte count from 1.0 to 1.5 x 10 9 /l and/or platelets from 75 to 99.9 x 1O 9 /1, 75% of full doses of both drugs was given; if the absolute granulocyte count ranged from 0.75 to 0.99 x 10 9 /l and/or platelet from 50 to 74.9 x in 9 /], 50% of full doses was given; chemotherapy was not administered if the absolute granulocyte count was < 0.75 x 10 9 /l and/or platelet < 50 x ln'/l. After dose reduction, full doses of both drugs were re-administered in the subsequent weeks only if the absolute granulocyte count was > 1. 5 10 9 /l and the platelet count Js 100 x 1O 9 /1. Re-evaluation of measurable lesions with CTscan and chest X-ray was performed after the second and third cycles of chemotherapy. After re-staging, treatment was planned for two more cycles depending on response and toxicity.
Results
Evaluation of activity and toxicity
Thirty-six consecutive, previously untreated patients with proven NSCLC entered the study; their characteristics are listed in Table 2 . Pathology included 13 adenocarcinomas, 12 squamous-cell carcinomas, eight undifferentiated carcinomas and three cytological diagnoses of NSCLC. The median age was 64 years (range 38-75); male : female ratio was 30 :6; performance status was 0 in 23 patients, 1 in 12 and 2 in one; the stage was IIIB in 13 patients and IV in 23. Ninety-seven courses (273 weekly administrations) were delivered for a median number of 3 (range 1-5). The median dose-intensity was 612 mg/m 2 per week for gemcitabine (82%) and 21 mg/m 2 per week for cisplatin (80%). All 36 patients were evaluable for toxicity, while 30 were assessable for response. Four patients died before re-evaluation (early deaths) due to progressive disease. Two patients were not evaluable due to protocol violations: a 51-year-old woman originally diagnosed with adenocarcinoma of the lung was subsequently suspected of having malignant mesothelioma; a 59-year-old man erroneously received methotrexate instead of cisplatin during the first weekly administration of the second course of chemotherapy. In this patient, toxicity of the first cycle is evaluated. These six patients were not considered for the calculation of response rate.
Response duration was calculated from onset of chemotherapy, and the median survival time from diagnosis.
Responses, according to WHO criteria, were as follows: 12 partial responses (40%, 95% CI: 22.5%-57.5%), seven in stage IIIB and five in stage IV; 14 stable disease (46.7%) and four progressive disease (13.3%). According to the intent-to-treat principle, response rate was 33.3% (12 out of 36 patients). Seven responses out of 12 (58.3%) were observed in patients receiving gemcitabine and cisplatin at dose-intensities below median values. WHO grade 3-4 myelotoxicity was as follows: thrombocytopenia in nine patients (25%), neutropenia in six (16.6%) and anemia in six (16.6%); seven patients (19.4%) omitted one weekly administration due to myelosuppression (two patients during the first course and five during the second). Emesis was mild; only two patients had WHO grade 3 vomit. No WHO grade 3-4 hepatic, renal or pulmonary toxicity, no infection and no treatment-related deaths were observed. Five patients (13.8%) and three patients (8.3%) omitted respectively, one and two weekly administrations due to nonhematologic toxicity. The median response duration was 9.9 months (range 4-23). The median survival time, calculated for all 36 patients entered, was 11.8 months (range 1-24, Figure 1 ). Fortyseven percent of patients were alive at one year after diagnosis. The median survival time was 13.7 months in stage IIIB and 8.3 months in stage IV patients. Of the patients in stage IIIB who responded, five had subsequent locoregional treatment: two had surgery and three had radiotherapy. Three of them are alive respectively at 23, 23 and 24 months from diagnosis (one treated with surgery and two treated with radiotherapy). Four stage IIIB and four stage IV patients received palliative radiotherapy.
Evaluation of performance status
Maintenance or improvement of performance status is one of the most important predictors of longer survival in patients with advanced NSCLC [14] .
In our study, we evaluated performance status at study entry and after two cycles of chemotherapy in 33 of 36 patients. Performance status was determined by the investigators. Five patients (15%) showed improvement (1 to 0), four patients (12%) had a worsening (respectively: 1 to 2; 0 to 1; 0 to 2; 2 to 3) and the remaining 24 patients (73%) had no change in their performance status (0 in 18 patients and 1 in six). Maintenance or improvement of performance status was obtained in 29 of 33 patients (88%). 
Discussion
NSCLC is a chemo-resistant neoplasm and only a few drugs, if used as single agents, produce objective responses in more than 15% of cases [15] . Cisplatin-based regimens are considered the best treatment for advanced NSCLC, although they produce only a modest advantage in overall survival [3, 4] . Some studies seem to demonstrate that chemotherapy is able to offer a symptomatic improvement in most patients [16, 17] . Unfortunately, the association of cisplatin with drugs such as mitomycin-C, ifosfamide, vindesine or vinblastine, in two or three drug regimens has shown significant toxicity. Gemcitabine activity as single agent in NSCLC, its favourable toxicity profile, and its synergistic interaction with cisplatin have generated great interest "among investigators. Numerous phase I and II clinical trials on this novel nucleoside analog, and on its combination with cisplatin have been recently conducted, but the optimal schedule of gemcitabine and cisplatin has not yet been defined.
In most phase II trials, cisplatin has been administered monthly at the dose of 100 mg/m 2 , while the dosage of gemcitabine has ranged from 1000 mg/m 2 to 1200 mg/m 2 per week. Response rates have ranged from 37% to 54%. WHO grade 3-4 myelosuppression, although usually short-lived, ranged from 52% to 58% and was responsible for the omission of gemcitabine administration on days 8 and/or 15 in a high percentage of chemotherapy courses in two studies [8, 13] .
The results of several studies, conducted to evaluate whether there is a correlation between cisplatin dosages (ranging from 60 to 200 mg/m 2 ) and its activity, are controversial [18] [19] [20] . However, 100 mg/m 2 of cisplatin, given every 21 or 28 days, can be considered the standard dose for most NSCLC cisplatin-based regimens.
Nevertheless, clinical studies have suggested that a weekly administration of cisplatin might increase its activity [21] [22] [23] with a more favourable toxicity profile and a simpler administration procedure. Moreover, the concurrent weekly administration of cisplatin with gemcitabine may optimize the activity of the combination due to repetition of the synergistic interaction [7] (three times per month), in comparison with the weekly gemcitabine and monthly cisplatin schedule. On the basis of these observations, Shepherd et al. conducted both a phase I and a phase II trial of weekly gemcitabine and cisplatin which resulted in a disappointing overall response rate of 26% [12] (Table 1) . However, in this study, a high percentage of patients (85%) had stage IV disease. In contrast, other studies such as those of Anton et al. [11] , Steward et al. [9] , Crino et al. [8] and Abratt et al. [10] , employing weekly gemcitabine and monthly cisplatin, showed a response rate ranging from 42% to 54% (Table 1 ). However, in these studies one-half or fewer of the patients had stage IV disease. In the study of Einhorn for the Hoosier Oncology Group, 83% of patients had stage IV disease and the response rate was 37% using the weekly gemcitabine and monthly cisplatin schedule [13] . These observations suggest that the divergent activities of the two schedules might be due to the patient characteristics (stage and performance status), rather than to the modality of the cisplatin administration.
A recent re-evaluation of data available from six phase II clinical trials of gemcitabine and cisplatin suggested a better activity of cisplatin delivery on days 2 or 15 rather than delivery on days 1 or 1, 8,15 [24] . In our study, using the weekly cisplatin and gemcitabine schedule, the response rate was very similar to that reported by the Hoosier Oncology Group (respectively 40% vs. 37%). Sixty-four percent of our patients had stage IV disease and, as expected, the majority of partial remissions were seen in stage IIIB patients (54% of stage IIIB and 22% of stage IV patients responded); this fact is consistent with the correlation of response rate with extent of disease in NSCLC clinical trials. Moreover, the median survival time was higher in patients with locally advanced than in those with metastatic disease (13.7 months in stage IIIB and 8.3 months in stage IV patients). With our schedule we observed an equivalent antitumor activity, but much less severe myelotoxicity compared to the other regimens that employed the same drugs (Table 1) . Moreover, we report a high degree of maintenance or improvement of performance status; this fact is of great interest owing to the high prognostic value of this parameter [14] as well as to its implications for the quality of life of treated patients. However, these results could be partially biased by the fact that assessment of the PS was made by the investigators.
These observations, along with the easier administration procedure (only 35 mg/m 2 of cisplatin per week) and high-dose intensity administered, make this schedule very interesting.
In the absence of randomised trials, it is difficult to establish which of the cisplatin-gemcitabine schedules is the best. Moreover, as an increase in response rate remains an unsatisfactory goal in the treatment of advanced NSCLC, phase III trials should aim at the improvement of survival and quality of life, with low toxicity in lung cancer patients.
